Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 October 2019 | Story Thabo Kessah | Photo Tshepo Moeketsi
Prof Pearl Sithole
Prof Pearl Sithole says higher education needs to create space for Africa to be contributors and innovators of knowledge.

“Excellence is my main priority. For me, excellence means mastery of cross-communicable science and liberation of intellectual creativity that is free of mere complacency and acknowledging the right to analyse from where we stand. I am unapologetic about indigenous knowledge being the basis for scientific advancement.” This is how the newly appointed Vice-Principal: Academic and Research, Prof Pearl Sithole, sums up her vision and plan for academia and research on the Qwaqwa Campus. 

She believes that the human mind is geared towards ‘seeking and constantly explaining itself in the service of innovative change.’ 

“With this service of innovative change fully realised, the Qwaqwa Campus will be able to produce students who can analyse, innovate, and solve real social and world problems. For me, this is the University of the Free State graduate I pine to see – and there had better be truth to the ‘free’ part of this intellectual soul! I see Qwaqwa as a site for this intellectual innovation catalyst,” she said.

Social anthropologist

Prof Sithole is a Social Anthropology graduate with both master’s and PhD degrees from the University of Cambridge in England. “I stumbled upon Anthropology as part of my three majors at the then University of Durban-Westville. This discipline confessed its previous conceptual sins in a way that inspired change! From the exploration of human origins, to economic and political developments, and that was Anthropology. I was just absolutely taken by its acknowledgement of the intellectual project being socio-culturally rooted,” she said about her chosen area of study.

“I have always been inspired by Archie Mafeje’s work. I was motivated by Bernard Magubane’s scholarship, and I marvelled at the rigour of Oyeronke Oyewumi and Marilyn Strathern in feminist discourse. I mention these, because they inspire intellectual passion in me and I eventually met them,” she added.

Higher education in SA

She believes the higher-education sector is succumbing to streamlining methods, uninformed processes, and very little impact. “Like in government, higher education should not suffer from reduction of people into statistics, interventions into annual performance plan targets, and planning and monitoring into sanitised expenditure against targets. I see the shortage of relevance, responsiveness, and humanness; as well as ‘being captured’ by the latest fashions of doing rigid academe as the major challenges of higher education in South Africa today. We need to liberate our own innovative potential. We really need to create space for Africa to be contributors and innovators of knowledge,” Prof Sithole, the author of Unequal Peers, said.

She is, however, optimistic about the future of higher education in South Africa. “The day that we will have our innovation systems and systems of defining excellence – liberated from merely kneeling before the altar of Westernisation – we will gain integrity both conceptually and instrumentally in terms of responding to a society that is waiting for higher education to solve societal problems. The solution is to let those who see this truth continue to produce the knowledge despite being less than pleasing to the average scientific oversight bodies steeped in conventional Western validation.”

Research interests

Prof Sithole was previously employed with the Public Service Commission as a commissioner, a position she held from 2015 to August 2019. Prior to that, she worked at the University of KwaZulu-Natal as an Associate Professor of Community Development from 2010 to 2015, and at the South African Human Sciences Research Council (HSRC) as a senior researcher from 2006 to 2010. Her research interests and areas of expertise are governance, gender and development, analysis of social inequality, and the politics of knowledge production.


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept